A new peer-review article has been published on PentaBase’s unique cancer diagnostic assay, SensiScreen® FFPE BRAF qPCR assay. The authors found that SensiScreen FFPE BRAF qPCR assay can contribute to a more specific, time and cost-saving approach to better identify and characterize mutations in patients affected by cancer, compared with some of the more traditional methods. To read the full article, please follow the link: https://doi.org/10.1371/journal.pone.0281558. If you are interested in SensiScreen® FFPE BRAF qPCR assay, please take a look at our homepage or contact us directly at info@pentabase.com.

Other articles you might find interesting:

A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies: https://doi.org/10.1371/journal.pone.0253687

SensiScreen® KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations: https://doi.org/10.1371/journal.pone.0178027